Singh Pritpal
1 Department of Pharmacy, St Peter's Hospital, Albany, NY, USA.
2 Division of Pharmacovigilance II, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
J Pharm Pract. 2018 Apr;31(2):230-233. doi: 10.1177/0897190017699774. Epub 2017 Mar 27.
Anagrelide is an established treatment option for essential thrombocythemia (ET). Cardiovascular adverse events can occur with its use including heart failure and cardiomyopathy.
A 52-year-old African American male with ET presented with chest pain, shortness of breath, and dyspnea on exertion. His ET was managed with hydroxyurea 1500 mg by mouth twice a day and anagrelide 1 mg by mouth 3 times a day. The patient was receiving anagrelide for approximately 2 years prior to presentation. The patient's platelet count was 2.07 × 10 cells/mm. Transthoracic echocardiography revealed decreased left systolic dysfunction. Also, cardiac magnetic resonance imaging showed an increased left ventricle cavity size with severely depressed systolic dysfunction and an ejection fraction (EF) of 18%. Anagrelide therapy was discontinued and the patient was maintained on hydroxyurea for ET. Three months later, following treatment by a heart failure clinic, the patient's EF was 55%. Five months after discontinuation, the patient improved from New York Heart Association (NYHA) class II to NYHA class I.
A 52-year-old man with ET presented with an EF of 18% after 2 years of anagrelide therapy. His EF increased from 18% to 55% 3 months after discontinuation of anagrelide.
阿那格雷是原发性血小板增多症（ET）的一种既定治疗选择。使用该药可能会发生心血管不良事件，包括心力衰竭和心肌病。
一名52岁患有ET的非裔美国男性出现胸痛、呼吸急促和劳力性呼吸困难。他的ET通过每天口服两次1500毫克羟基脲和每天口服3次1毫克阿那格雷进行治疗。在就诊前，该患者接受阿那格雷治疗约2年。患者的血小板计数为2.07×10⁹/升。经胸超声心动图显示左心室收缩功能下降。此外，心脏磁共振成像显示左心室腔大小增加，收缩功能严重受损，射血分数（EF）为18%。停用阿那格雷治疗，患者继续使用羟基脲治疗ET。三个月后，在心力衰竭诊所治疗后，患者的EF为55%。停药五个月后，患者从纽约心脏协会（NYHA）II级改善为NYHA I级。
一名52岁患有ET的男性在接受阿那格雷治疗2年后出现EF为18%。停用阿那格雷3个月后，他的EF从18%增加到55%。
